Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Inclusion Criteria:

   - Newly diagnosed neuroblastoma (NBL) or ganglioneuroblastoma with tumor-associated
   opsoclonus-myoclonus-ataxia syndrome (OMA)

      - Patients with NBL diagnosed within 6 months of OMA diagnosis AND patients with
      OMA diagnosed within 6 months of NBL diagnosis are eligible

      - Must enroll on study within 4 weeks of diagnosis

      - Presence of opsoclonus, myoclonus, and/or ataxia associated with neuroblastoma
      considered eligible

   - Currently enrolled on COG neuroblastoma protocols: COG-ANBL00B1 or its successor

   - Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on
   age/gender as follows:

      - ≤ 0.4 mg/dL (for patients 1 to 5 months of age)

      - ≤ 0.5 mg/dL (for patients 6 to 11 months of age)

      - ≤ 0.6 mg/dL (for patients 1 year of age)

      - ≤ 0.8 mg/dL (for patients 2 to 5 years of age)

      - ≤ 1.0 mg/dL (for patients 6 to 9 years of age)

      - ≤ 1.2 mg/dL (for patients 10 to 12 years of age)

      - ≤ 1.4 mg/dL (for female patients ≥ 13 years of age)

      - ≤ 1.5 mg/dL (for male patients 13 to 15 years of age)

      - ≤ 1.6 mg/dL (for male patients ≥ 16 years of age)

   - No prior IV gamma globulin therapy

   - No prior chemotherapy

   - Concurrent chemotherapy allowed

   - No prior prednisone or corticotropin

      - Patients who have received ≤ 14 days of steroids are eligible

   - Concurrent surgery allowed